secwatch / observer
8-K filed July 13, 2026, 9:10 AM ET ticker ESPR CIK 0001434868
M&A confidence high sentiment neutral materiality 1.00

Esperion acquired by Essence Parent for $3.16/share plus CVRs; merger closed July 13, 2026

Esperion Therapeutics, Inc.

item 1.01item 1.02item 2.01item 2.03item 3.01item 3.03item 5.01item 5.03item 5.02item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Robert E. Hoffman

director
ESPR · Esperion Therapeutics, Inc.
Effective
2026-07-13
Filed
July 13, 2026, 9:10 AM ET
Effective upon the consummation of the Merger, in accordance with the Merger Agreement, each of J. Martin Carroll, Sheldon L. Koenig, Robert E. Hoffman, Craig Thompson, Jay P. Shepard and Seth H.Z. Fischer, who constituted the board of directors of the Company immediately prior to the Effective Time, ceased to be directors of the Company, and Justin Bateman and Ankit Pareek, the directors of MergerCo immediately prior to the Effective Time, were elected as directors of the Company.
Departed

Sheldon L. Koenig

director
ESPR · Esperion Therapeutics, Inc.
Effective
2026-07-13
Filed
July 13, 2026, 9:10 AM ET
Effective upon the consummation of the Merger, in accordance with the Merger Agreement, each of J. Martin Carroll, Sheldon L. Koenig, Robert E. Hoffman, Craig Thompson, Jay P. Shepard and Seth H.Z. Fischer, who constituted the board of directors of the Company immediately prior to the Effective Time, ceased to be directors of the Company, and Justin Bateman and Ankit Pareek, the directors of MergerCo immediately prior to the Effective Time, were elected as directors of the Company.
Departed

Seth H.Z. Fischer

director
ESPR · Esperion Therapeutics, Inc.
Effective
2026-07-13
Filed
July 13, 2026, 9:10 AM ET
Effective upon the consummation of the Merger, in accordance with the Merger Agreement, each of J. Martin Carroll, Sheldon L. Koenig, Robert E. Hoffman, Craig Thompson, Jay P. Shepard and Seth H.Z. Fischer, who constituted the board of directors of the Company immediately prior to the Effective Time, ceased to be directors of the Company, and Justin Bateman and Ankit Pareek, the directors of MergerCo immediately prior to the Effective Time, were elected as directors of the Company.
Departed

Jay P. Shepard

director
ESPR · Esperion Therapeutics, Inc.
Effective
2026-07-13
Filed
July 13, 2026, 9:10 AM ET
Effective upon the consummation of the Merger, in accordance with the Merger Agreement, each of J. Martin Carroll, Sheldon L. Koenig, Robert E. Hoffman, Craig Thompson, Jay P. Shepard and Seth H.Z. Fischer, who constituted the board of directors of the Company immediately prior to the Effective Time, ceased to be directors of the Company, and Justin Bateman and Ankit Pareek, the directors of MergerCo immediately prior to the Effective Time, were elected as directors of the Company.
Appointed

Ankit Pareek

director
ESPR · Esperion Therapeutics, Inc.
Effective
2026-07-13
Filed
July 13, 2026, 9:10 AM ET
Effective upon the consummation of the Merger, in accordance with the Merger Agreement, each of J. Martin Carroll, Sheldon L. Koenig, Robert E. Hoffman, Craig Thompson, Jay P. Shepard and Seth H.Z. Fischer, who constituted the board of directors of the Company immediately prior to the Effective Time, ceased to be directors of the Company, and Justin Bateman and Ankit Pareek, the directors of MergerCo immediately prior to the Effective Time, were elected as directors of the Company.
Departed

J. Martin Carroll

director
ESPR · Esperion Therapeutics, Inc.
Effective
2026-07-13
Filed
July 13, 2026, 9:10 AM ET
Effective upon the consummation of the Merger, in accordance with the Merger Agreement, each of J. Martin Carroll, Sheldon L. Koenig, Robert E. Hoffman, Craig Thompson, Jay P. Shepard and Seth H.Z. Fischer, who constituted the board of directors of the Company immediately prior to the Effective Time, ceased to be directors of the Company, and Justin Bateman and Ankit Pareek, the directors of MergerCo immediately prior to the Effective Time, were elected as directors of the Company.
Appointed

Justin Bateman

director
ESPR · Esperion Therapeutics, Inc.
Effective
2026-07-13
Filed
July 13, 2026, 9:10 AM ET
Effective upon the consummation of the Merger, in accordance with the Merger Agreement, each of J. Martin Carroll, Sheldon L. Koenig, Robert E. Hoffman, Craig Thompson, Jay P. Shepard and Seth H.Z. Fischer, who constituted the board of directors of the Company immediately prior to the Effective Time, ceased to be directors of the Company, and Justin Bateman and Ankit Pareek, the directors of MergerCo immediately prior to the Effective Time, were elected as directors of the Company.
Departed

Craig Thompson

director
ESPR · Esperion Therapeutics, Inc.
Effective
2026-07-13
Filed
July 13, 2026, 9:10 AM ET
Effective upon the consummation of the Merger, in accordance with the Merger Agreement, each of J. Martin Carroll, Sheldon L. Koenig, Robert E. Hoffman, Craig Thompson, Jay P. Shepard and Seth H.Z. Fischer, who constituted the board of directors of the Company immediately prior to the Effective Time, ceased to be directors of the Company, and Justin Bateman and Ankit Pareek, the directors of MergerCo immediately prior to the Effective Time, were elected as directors of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert E. Hoffman departed as director at Esperion Therapeutics, Inc..

Action
ceased to be director
Role
director
Exact text from the filing
Effective upon the consummation of the Merger, in accordance with the Merger Agreement, each of J. Martin Carroll, Sheldon L. Koenig, Robert E. Hoffman, Craig Thompson, Jay P. Shepard and Seth H.Z. Fischer, who constituted the board of directors of the Company immediately prior to the Effective Time, ceased to be directors of the Company, and Justin Bateman and Ankit Pareek, the directors of MergerCo immediately prior to the Effective Time, were elected as directors of the Company.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Sheldon L. Koenig departed as director at Esperion Therapeutics, Inc..

Action
ceased to be director
Role
director
Exact text from the filing
Effective upon the consummation of the Merger, in accordance with the Merger Agreement, each of J. Martin Carroll, Sheldon L. Koenig, Robert E. Hoffman, Craig Thompson, Jay P. Shepard and Seth H.Z. Fischer, who constituted the board of directors of the Company immediately prior to the Effective Time, ceased to be directors of the Company, and Justin Bateman and Ankit Pareek, the directors of MergerCo immediately prior to the Effective Time, were elected as directors of the Company.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Seth H.Z. Fischer departed as director at Esperion Therapeutics, Inc..

Action
ceased to be director
Role
director
Exact text from the filing
Effective upon the consummation of the Merger, in accordance with the Merger Agreement, each of J. Martin Carroll, Sheldon L. Koenig, Robert E. Hoffman, Craig Thompson, Jay P. Shepard and Seth H.Z. Fischer, who constituted the board of directors of the Company immediately prior to the Effective Time, ceased to be directors of the Company, and Justin Bateman and Ankit Pareek, the directors of MergerCo immediately prior to the Effective Time, were elected as directors of the Company.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Jay P. Shepard departed as director at Esperion Therapeutics, Inc..

Action
ceased to be director
Role
director
Exact text from the filing
Effective upon the consummation of the Merger, in accordance with the Merger Agreement, each of J. Martin Carroll, Sheldon L. Koenig, Robert E. Hoffman, Craig Thompson, Jay P. Shepard and Seth H.Z. Fischer, who constituted the board of directors of the Company immediately prior to the Effective Time, ceased to be directors of the Company, and Justin Bateman and Ankit Pareek, the directors of MergerCo immediately prior to the Effective Time, were elected as directors of the Company.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Ankit Pareek was elected as director at Esperion Therapeutics, Inc..

Action
elected
Role
director
Exact text from the filing
Effective upon the consummation of the Merger, in accordance with the Merger Agreement, each of J. Martin Carroll, Sheldon L. Koenig, Robert E. Hoffman, Craig Thompson, Jay P. Shepard and Seth H.Z. Fischer, who constituted the board of directors of the Company immediately prior to the Effective Time, ceased to be directors of the Company, and Justin Bateman and Ankit Pareek, the directors of MergerCo immediately prior to the Effective Time, were elected as directors of the Company.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

J. Martin Carroll departed as director at Esperion Therapeutics, Inc..

Action
ceased to be director
Role
director
Exact text from the filing
Effective upon the consummation of the Merger, in accordance with the Merger Agreement, each of J. Martin Carroll, Sheldon L. Koenig, Robert E. Hoffman, Craig Thompson, Jay P. Shepard and Seth H.Z. Fischer, who constituted the board of directors of the Company immediately prior to the Effective Time, ceased to be directors of the Company, and Justin Bateman and Ankit Pareek, the directors of MergerCo immediately prior to the Effective Time, were elected as directors of the Company.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Justin Bateman was elected as director at Esperion Therapeutics, Inc..

Action
elected
Role
director
Exact text from the filing
Effective upon the consummation of the Merger, in accordance with the Merger Agreement, each of J. Martin Carroll, Sheldon L. Koenig, Robert E. Hoffman, Craig Thompson, Jay P. Shepard and Seth H.Z. Fischer, who constituted the board of directors of the Company immediately prior to the Effective Time, ceased to be directors of the Company, and Justin Bateman and Ankit Pareek, the directors of MergerCo immediately prior to the Effective Time, were elected as directors of the Company.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Craig Thompson departed as director at Esperion Therapeutics, Inc..

Action
ceased to be director
Role
director
Exact text from the filing
Effective upon the consummation of the Merger, in accordance with the Merger Agreement, each of J. Martin Carroll, Sheldon L. Koenig, Robert E. Hoffman, Craig Thompson, Jay P. Shepard and Seth H.Z. Fischer, who constituted the board of directors of the Company immediately prior to the Effective Time, ceased to be directors of the Company, and Justin Bateman and Ankit Pareek, the directors of MergerCo immediately prior to the Effective Time, were elected as directors of the Company.
View on SEC.gov

Esperion Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001104659-26-082926
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.